Bank Of America Corp Mirati Therapeutics, Inc. Transaction History

Bank Of America Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $12.3 Million - $18.2 Million	-291,756 Reduced 89.02%	36,000 $2.12 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $2.11 Million - $2.89 Million	-58,494 Reduced 15.14%	327,756 $11.8 Million
Q1 2023 May 12, 2023	BUY	$36.54 - $54.26 $3.04 Million - $4.51 Million	83,132 Added 27.43%	386,250 $14.4 Million
Q4 2022 Feb 10, 2023	BUY	$41.27 - $98.62 $1.74 Million - $4.16 Million	42,229 Added 16.19%	303,118 $13.7 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $4.73 Million - $6.89 Million	79,434 Added 43.78%	260,889 $18.2 Million
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $74,834 - $169,524	1,911 Added 1.06%	181,455 $12.2 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $8.22 Million - $16.4 Million	108,406 Added 152.39%	179,544 $14.8 Million
Q4 2021 Feb 08, 2022	SELL	$132.01 - $190.29 $6.05 Million - $8.73 Million	-45,855 Reduced 39.19%	71,138 $10.4 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $13.2 Million - $17.8 Million	-100,238 Reduced 46.14%	116,993 $20.7 Million
Q2 2021 Sep 13, 2021	BUY	$144.0 - $179.73 $31.3 Million - $39 Million	217,231 New	217,231 $35.1 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.